Effects of Cannabidiol on Canine Immune Cells
Author Information
Author(s): Kosukwatthana Phannicha, Rungsuriyawiboon Oumaporn, Rattanasrisomporn Jatuporn, Kimram Kanogwan, Tansakul Natthasit
Primary Institution: Kasetsart University
Hypothesis
This study investigates the cytotoxicity and immunomodulatory effects of cannabidiol on canine PBMCs in LPS-stimulated and epileptic dogs.
Conclusion
Cannabidiol may reduce pro-inflammatory cytokine levels in canine PBMCs, suggesting potential therapeutic applications for inflammatory and neurological conditions.
Supporting Evidence
- Cannabidiol concentrations of 16 µg/mL significantly affected the viability of canine PBMCs.
- CBD reduced the production of pro-inflammatory cytokines in a dose-dependent manner.
- IL-6 levels decreased from 0.725 ng/mL to 0.525 ng/mL after CBD treatment in epileptic dogs.
- TNF-α levels significantly decreased from 179.05 pg/mL to 106.99 pg/mL after CBD treatment.
Takeaway
This study found that cannabidiol can help reduce inflammation in dogs, which might be useful for treating conditions like epilepsy.
Methodology
The study involved two parts: one assessing the effects of CBD on healthy canine PBMCs and another on PBMCs from epileptic dogs treated with CBD for 30 days.
Potential Biases
Potential bias due to the small number of participants and the variability in health status and treatment regimens of the dogs.
Limitations
The study had a small sample size and varied CBD dosages among dogs, which may affect the results.
Participant Demographics
The study included six healthy German shepherds and five dogs with refractory epilepsy, aged 2 to 6 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website